4.7 Article

Investigation on the solid-phase synthesis of silybin prodrugs and their timed-release

期刊

BIOORGANIC & MEDICINAL CHEMISTRY
卷 50, 期 -, 页码 -

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2021.116478

关键词

Solid phase synthesis; Timed-release prodrug; Silibinin; Silybin; Alzheimer's disease

向作者/读者索取更多资源

This study presents an efficient solid-phase approach for obtaining new prodrugs of silybins conjugated with uridine and adenosine as pro-moieties, with improved solubility and potential for controlled drug release. Uridine conjugates were found to be quickly cleaved by RNase A, releasing the active drug, without exhibiting toxicity in neuroblastoma cells. These results encourage further exploration of uridine-silybin prodrugs for potential therapeutic applications.
Prodrugs are ingenious derivatives of therapeutic agents designed to improve the pharmacokinetic profile of the drug. Here, we report an efficient and regioselective solid phase approach for obtaining new prodrugs of 9 '' silybins conjugated with 3 '-ribonucleotide units (uridine and adenosine) as pro-moieties. Uridine and adenosine conjugates were obtained in good yields (41-50%), beginning with silibinin and its diastereomers (silybin A and silybin B), using a NovaSyn (R) support functionalized with an ad hoc linker, which allowed selective detachment of only the desired products. As expected, the solubility of both uridine and adenosine conjugates was higher than that of the parental natural product (5 mg/mL and 3 mg/mL for uridine and adenosine, respectively). Our investigations revealed that uridine conjugates were quickly cleaved by RNase A, releasing silybin drugs, even at low enzyme concentrations. No toxic effects were found for any ribonucleotide conjugate on differentiated neuroblastoma SH-SY5Y cells when tested at increasing concentrations. All results strongly encourage further investigations of uridine-silybin prodrugs as potential therapeutic agents for both oral and intravenous administration. The present synthetic approach represents a valuable strategy to the future design of new prodrugs with modified nucleoside pro-moieties to modulate the pharmacokinetics of silybins or different natural products with strong pharmacological activities but poor bioavailability.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据